Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 44, 2009, Pages 18745-18750

  Sears, D D ^a   Hsiao, G ^b   Hsiao, A ^b   Yu, J G ^a   Courtney, C H ^a   Ofrecio, J M ^a   Chapman, J ^c   Subramaniam, S ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c PFIZER INC   (United States)

Author keywords

Branched chain amino acid (BCAA); Diabetes; Inflammation; Muscle and adipose tissue; Transcriptional mechanisms

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIGEN; GLUCOSE; HLA DR ANTIGEN; MLXIP ANTIGEN; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOPSY TECHNIQUE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MITOCHONDRIAL RESPIRATION; PHENOTYPE; PRIORITY JOURNAL; SENSITIZATION; SKELETAL MUSCLE; TREATMENT RESPONSE;

ADIPOCYTES; ADIPOSE TISSUE; BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MITOCHONDRIA; MUSCLE, SKELETAL; THIAZOLIDINEDIONES;

EID: 73249123069     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0903032106     Document Type: Article

References (35)

1. Despres JP, et al. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. The New Eng J Med 334:952-957.
2. Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Jr, Lenfant C (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Associa-tion conference on scientific issues related to definition. Circulation 109:433-438.
3. Sinha R, et al. (2002) Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: Relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 51:1022-1027.
4. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860-867.
5. Matsuzawa Y (2006) The metabolic syndrome and adipocytokines. FEBS Lett 580:2917-2921.
6. Dahlman I, et al. (2006) Down-regulation of electron transport chain genes in visceral adipose tissue in type 2 diabetes independent of obesity and possibly involving tumor necrosis factor-alpha. Diabetes 55:1792-1799.
7. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet 34:267-273.
8. Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106:467-472.
9. Igarashi M, et al. (2007) Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: A comparison of responders and non-responders. Diabetes Res Clin Pract 77:389-398.
10. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203.
11. Lapsys NM, et al. (2000) Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. J Clin Endocrinol Metab 85:4293-4297.
12. Desvergne B, Michalik L, Wahli W (2006) Transcriptional regulation of metabolism. Physiol Rev 86:465-514.
13. Arner P (2003) The adipocyte in insulin resistance: Key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14:137-145.
14. Fruebis J, et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010.
15. Herman MA,Kahn BB (2006) Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest 116:1767-1775.
16. Toyoshima Y, et al. (2005) Leptin improves insulin resistance and hyperglycemia in amouse model of type 2 diabetes. Endocrinology 146:4024-4035.
17. Yamauchi T, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946.
18. Hsiao A, Ideker T, Olefsky JM, Subramaniam S (2005) VAMPIRE microarray suite:Aweb-based platform for the interpretation of gene expression data. Nucleic Acids Res 33:W627-632.
19. Kanehisa M, et al. (2006) From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res 34:D354-357.
20. Araki T, et al. (2005) Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes. Osaka City Med J 51:19-25.
21. Sans CL, Satterwhite DJ, Stoltzman CA, Breen KT, Ayer DE (2006) MondoA-Mlx het-erodimers are candidate sensors of cellular energy status: Mitochondrial localization and direct regulation of glycolysis. Mol Cell Biol 26:4863-4871.
22. Muoio DM, Newgard CB (2008)Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9:193-205.
23. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM (2006) Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55:2277-2285.
24. Neels JG, Olefsky JM (2006) Inflamed fat: What starts the fire? J Clin Invest 116:33-35.
25. Bogacka I, Xie H, Bray GA, Smith SR (2005) Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54:1392-1399.
26. Choo HJ, et al. (2006) Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia 49:784-791.
27. Rong JX, et al. (2007) Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes 56:1751-1760.
28. Wilson-Fritch L, et al. (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281-1289.
29. Yu JG, et al. (2002)The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974.
30. Frias JP,Yu JG, Kruszynska YT, Olefsky JM(2000) Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23:64-69.
31. Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430.
32. Wolfe RR (1984) Tracers in metabolic research: Radioisotope and stable isotope/mass spectrometry methods. Lab Res Methods Biol Med 9:1-287.
33. Desbuquois B, Aurbach GD (1971) Use of polyethylene glycol to separate free and anti-body-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732-738.
34. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S (2004) Variance-modeled posterior inference of microarray data: Detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 20:3108-3127.
35. Glantz SA (2005) Primer of Biostatistics (McGraw-Hill Medical Pub Division, New York) 6th Ed, p 520.